Information Provided By:
Fly News Breaks for August 31, 2018
MEIP
Aug 31, 2018 | 08:58 EDT
Oppenheimer analyst Leah Rush Cann raised her price target for MEI Pharma to $7.50 after adjusting her risk discount to reflect the planned registration study for ME-401. The analyst believes the clinical programs are advancing and keeps an Outperform rating on the shares. She anticipates MEI will commercialize its development-stage drug Pracinostat in acute myeloid leukemia and myeloid dysplastic syndromes, and ME-401 in chronic lymphocytic leukemia and follicular lymphoma, in 2022.
News For MEIP From the Last 2 Days
There are no results for your query MEIP
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.